Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Neurocognitive Impairment in Inherited Metabolic Disorders due to Intoxication and Energy Defects, A Systematic Review

  • Gil-González, Marta
  • Arias, Carolina
  • Saudubray, Jean-Marie
  • Colomé-Roura, Roser
  • García-Cazorla, Ángeles
Inherited metabolic disorders (IMD) can disrupt brain development and functioning, leading to cognitive and behavioral abnormalities. This systematic review aims to provide a comprehensive synthesis of the evidence regarding neurocognitive impairments in intoxication IMD due to the accumulation of small molecule disorders and energy-related IMD. A search was conducted in the PubMed database until August 2024, using the term "cognition" and up to 421 energy-related IMD and 196 intoxication IMD. Reviews, animal models, studies with non-standardized measures, and studies that focused on complex molecule disorders, small molecule deficiencies, and phenylketonuria were excluded. In total, 163 studies were included in the final analysis. The cognitive domains assessed were executive functions, attention, processing speed, language, speech, visual performance, fine motor dexterity, memory, behavioral and emotional regulation, and social cognition. Most available evidence focused on intoxication IMD (83%), which exhibited better global cognitive functioning than energy defects. The cognitive domains most frequently reported as impaired were fine motor dexterity (80.9%), behavioral and emotional regulation (80%), executive functions (73.3%), attention (72.4%), and social cognition (65.6%). After applying the chi-square test with a 95% confidence level, no statistically significant differences were found between intoxication and energy-related IMD. However, language impairments were slightly more pronounced in intoxication disorders, while visuospatial deficits were more common in energy disorders. Individuals with IMD are at a higher risk of neurodevelopmental disorders, which can persist despite early detection and treatment. Although the number of cognitive studies has increased in recent years, further research with standardized measures is necessary to understand the underlying pathophysiology of neurocognitive impairments.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Tetrahydrobiopterin (BH4) treatment stabilizes tyrosine hydroxylase, Rescue of tyrosine hydroxylase deficiency phenotypes in human neurons and in a knock-in mouse model

  • Jung-KC, Kunwar|||0000-0002-6745-7318
  • Tristán Noguero, Alba|||0000-0002-0170-9762
  • Altankhuyag, Altanchimeg
  • Piñol Belenguer, David|||0000-0001-7490-5054
  • Prestegård, Karina S.|||0000-0003-3706-6751
  • Fernandez Carasa, Irene|||0000-0002-8195-3510
  • Colini Baldeschi, Arianna|||0000-0002-8638-3705
  • Sigatulina Bondarenko, Maria
  • García-Cazorla, Angels|||0000-0001-9853-688X
  • Consiglio, Antonella
  • Martinez, Aurora|||0000-0003-1643-6506
Proteostatic regulation of tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine biosynthesis, is crucial for maintaining proper brain neurotransmitter homeostasis. Variants of the TH gene are associated with tyrosine hydroxylase deficiency (THD), a rare disorder with a wide phenotypic spectrum and variable response to treatment, which affects protein stability and may lead to accelerated degradation, loss of TH function and catecholamine deficiency. In this study, we investigated the effects of the TH cofactor tetrahydrobiopterin (BH) on the stability of TH in isolated protein and in DAn- differentiated from iPSCs from a human healthy subject, as well as from THD patients with the R233H variant in homozygosity (THDA) and R328W and T399M variants in heterozygosity (THDB). We report an increase in TH and dopamine levels, and an increase in the number of TH+ cells in control and THDA cells. To translate this in vitro effect, we treated with BH a knock-in THD mouse model with Th variant corresponding to R233H in patients. Importantly, treatment with BH significantly improved motor function in these mice, as demonstrated by increased latency on the rotarod test and improved horizontal activity (catalepsy). In conclusion, our study demonstrates the stabilizing effects of BH on TH protein levels and function in THD neurons and mice, rescuing disease phenotypes and improving motor outcomes. These findings highlight the therapeutic potential of BH as a treatment option for THDA patients with specific variants and provide insights into the modulation of TH stability and its implications for THD management.